Weaver syndrome and EZH2 mutations: Clarifying the clinical phenotype.

Details

Serval ID
serval:BIB_FFE9E5A8B5E3
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Weaver syndrome and EZH2 mutations: Clarifying the clinical phenotype.
Journal
American Journal of Medical Genetics. Part A
Author(s)
Tatton-Brown K., Murray A., Hanks S., Douglas J., Armstrong R., Banka S., Bird L.M., Clericuzio C.L., Cormier-Daire V., Cushing T., Flinter F., Jacquemont M.L., Joss S., Kinning E., Lynch S.A., Magee A., McConnell V., Medeira A., Ozono K., Patton M., Rankin J., Shears D., Simon M., Splitt M., Strenger V., Stuurman K., Taylor C., Titheradge H., Van Maldergem L., Temple I.K., Cole T., Seal S., Rahman N., Rahman N.
Working group(s)
Childhood Overgrowth Consortium
Contributor(s)
Addor M.C., Akgul M., Amor D., Anderson K., Anderson R., Andries S., Archer H., Armstrong R., Ashton-Prolla P., Bahceci M., Baralle D., Barnicoat A., Barrow M., Baujat G., Baynam G., Beales P., Becker K., Beckh-Arnold E., Ben-Yehuda A., Berg J., Bernhard B., Bhal S., Bhat M., Birch J., Bird L., Bitner M., Blair E., Bliek J., Blyth M., Bottani A., Bradley L., Brady A., Breatnach F., Brueton L., Buehler B., Burke A., Burn J., Campbell J., Canham N., Castle B., Chandler K., Chandrasena R., Chang E., Chu C., Christenden C., Cilliers D., Clarke A., Clayton-Smith J., Clericuzio C., Clowes V., Cole T., Colley A., Collins A., Connell F., Cook J., Cordeiro H., Crocker C., Crow Y., Culic V., Cushing T., Dabir T., Dalton A., Danda S., Davidson R., Davies S., Day R., De Roy M., de Soberanis V., Dearnaley D., Dennis N., Deshpande C., Desouza B., Devlin L., Differ AM., Dinwiddie R., Dixit A., Dobbie A., Dominguez J., Donaldson A., Donnai D., Doz M., Dupont J., Eastwood D., Edwards M., Ellis I., Elmslie F., Evans R., Faravelli F., Firth H., Fisher R., Fiskerstrand T., Fitzpatrick D., Flanagan A., Flinter F., Foley P., Foulds N., Foulkes W., Franklin J., Fryer A., Gallagher A., Garcia S., Gardiner C., Gardner M., Garrett C., Gener B., Gerrard M., Gibbons R., Gillerot Y., Goel H., Goudie D., Gowrishankar K., Graham C., Green A., Gregersen N., Hale J., Harper J., Harrison R., Hughes H., Henderson A., Henman P., Hennekam R., Hobson E., Holder M., Holder S., Homfray T., Horovitz D., Huma Z., Hurst J., Hwu WL., Irvine A., Irving M., Izatt L., Jacquemont ML., Jagadeesh S., Jenkins L., Jessen C., Johnson D., Jones E., Jones L., Josifova D., Joss S., Kanabar , Kannu P., Keppler-Noreuil K., Kerr B., Kingston H., Kingston J., Kini U., Kinning E., Krause A., Kumar A., Kumar D., Lachlan K., Lam W., Lapunzina P., Lees M., Leonard N., Lewis I., Liebelt J., Livesey A., Longman C., Lopponen T., Lozano , Lucassen A., Lunt P., Lynch SA., Lyonnet S., MacDonnell J., Magee A., Maher E., Maitz S., Male A., Mansour S., McConnell V., McDevitt T., McEntagart M., McGillivray G., McGowan R., McKee S., McKeown C., Meany C., Medeira A., Mehta S., Meiner V., Metcalfe K., Milstein K., Mohammed S., Monaghan G., Montgomery T., Morgan A., Morland B., Morrison P., Morton J., Mudgal R., Munaza A., Murday V., Nampoothiri S., Nathanson K., Neas K., Nemeth A., Neri G., Newbury-Ecob R., Ockeloen C., Oley C., Owen C., Ozono K., Panarello C., Park SM., Parker M., Patel C., Patton M., Payne S., Pilz D., Pinkney M., Plecko B., Pocha M., Pottinger C., Prescott K., Price S., Pritchard-Jones K., Proctor A., Quarrell O., Raith W., Rankin J., Raymond L., Rea G., Reardon W., Reid E., Rees H., Rittinger O., Robards M., Roposch A., Rosser E., Rothschild A., Rourke D., Ruddy D., Saggar A., Saleh N., Saletti V., Sampson J., Sandford R., Santos H., Sarkar A., Scott R., Scurr I., Selicorni A., Semple R., Sharif S., Shaw A., Shaw-Smith C., Shears D., Shelagh J., Simon M., Smith G., Smithson S., Splitt M., Stevens M., Stewart A., Stopps K., Stuurman K., Suri M., Swain A., Tanateles G., Taylor A., Taylor C., Teixeira M., Temple K., Thomas E., Thompson E., Thonney F., Tischowitz M., Tolmie J., Tomkins S., Turkmen S., Turner A., Turnpenny P., Van-Haelst M., Van Maldergem L., Vasudevan P., Verellen C., Verma IC., Vigneron J., Wakeling E., Wainwright L., Walker L., Wheeler P., White K., Williams D., Wilson L., Winter R., Woods G., Wright M., Yachelevich N., Yeung A., Zankl A., Stewart F., Stewart H., Sweeney E.
ISSN
1552-4833 (Electronic)
ISSN-L
1552-4825
Publication state
Published
Issued date
2013
Volume
161A
Number
12
Pages
2972-2980
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish. Addor M.C. fait partie de Childhood Overgrowth Consortium
Abstract
Weaver syndrome, first described in 1974, is characterized by tall stature, a typical facial appearance, and variable intellectual disability. In 2011, mutations in the histone methyltransferase, EZH2, were shown to cause Weaver syndrome. To date, we have identified 48 individuals with EZH2 mutations. The mutations were primarily missense mutations occurring throughout the gene, with some clustering in the SET domain (12/48). Truncating mutations were uncommon (4/48) and only identified in the final exon, after the SET domain. Through analyses of clinical data and facial photographs of EZH2 mutation-positive individuals, we have shown that the facial features can be subtle and the clinical diagnosis of Weaver syndrome is thus challenging, especially in older individuals. However, tall stature is very common, reported in >90% of affected individuals. Intellectual disability is also common, present in ~80%, but is highly variable and frequently mild. Additional clinical features which may help in stratifying individuals to EZH2 mutation testing include camptodactyly, soft, doughy skin, umbilical hernia, and a low, hoarse cry. Considerable phenotypic overlap between Sotos and Weaver syndromes is also evident. The identification of an EZH2 mutation can therefore provide an objective means of confirming a subtle presentation of Weaver syndrome and/or distinguishing Weaver and Sotos syndromes. As mutation testing becomes increasingly accessible and larger numbers of EZH2 mutation-positive individuals are identified, knowledge of the clinical spectrum and prognostic implications of EZH2 mutations should improve.
Pubmed
Web of science
Create date
16/01/2014 11:52
Last modification date
20/08/2019 17:30
Usage data